Skip to main content
ARGX
NASDAQ Life Sciences

argenx Completes $2.2B Acquisition of Forte Biosciences; Tender Offer Expires with 87.13% Tendered

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,018.58
Mkt Cap
$65.429B
52W Low
$661.85
52W High
$1,058.69
52W Position info
54% above low
Off High info
3.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ARGX sits 54% above its 52-week low of $661.85.

Summary

argenx completed its $2.2 billion acquisition of Forte Biosciences after 87.13% of shares were tendered at $77.00 per share. The merger closed under Section 251(h), and Forte will be delisted from Nasdaq.


Key Events · M&A and Partnerships · ARGX

  • Tender Offer Expires with 87.13% Tendered

    19,894,879 Forte shares were validly tendered at $77.00 per share, representing 87.13% of outstanding shares including argenx's existing holdings, satisfying the Minimum Condition.

  • Merger Completed Under Section 251(h)

    argenx's subsidiary merged with and into Forte without a stockholder vote, converting all remaining shares into the right to receive $77.00 per share in cash.

  • Forte to Be Delisted from Nasdaq

    Forte's shares are expected to cease trading on the Nasdaq Capital Market prior to market open on August 27, 2026, with deregistration to follow.

  • FB102 Added to argenx Pipeline

    The acquisition brings FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, with Phase 2 celiac and Phase 1b alopecia areata data expected in H2 2026.


Analysis · ARGX · Life Sciences

argenx has closed its $2.2 billion all-cash acquisition of Forte Biosciences, with 19,894,879 shares validly tendered — representing 87.13% of outstanding shares including argenx's existing stake. The merger was completed under Section 251(h) without a stockholder vote, and Forte's shares will be delisted from Nasdaq. This adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx's immunology pipeline. The deal expands argenx's portfolio beyond its blockbuster FcRn franchise and positions it to pursue diseases driven by T-cell and NK-cell activity.

How filings like this one have moved

In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARGX was trading at $1,018.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.4B. The 52-week trading range was $661.85 to $1,058.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARGX - Latest Insights

ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $892.53 info
Change: +$38.53 (+5%) info
Market Cap: $56.638B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $892.53 info
Change: +$97.33 (+12%) info
Market Cap: $56.638B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $892.53 info
Change: +$101.53 (+13%) info
Market Cap: $56.638B info
ARGX
Sep 29, 2026, 8:38 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $970.55
Real-time Price: $892.53 info
Change: -$78.02 (-8%) info
Market Cap: $56.638B info
ARGX
Aug 19, 2026, 7:48 AM EDT
Filing Type: SC TO-T/A
Importance Score:
7
Price at Filing: $1,015.76
Real-time Price: $892.53 info
Change: -$123.23 (-12%) info
Market Cap: $56.638B info